CAR T-Cell Therapy Market Trends, Share, Demand, Competition, Revenue and Future Outlook: SPER Market Research

Q: How can I get a sample report on the CAR T-Cell Therapy Market?

You can get the sample pages by clicking the link - Click Here

Published: Oct 2024	Report ID: PHAR2414	Pages: 1 - 237	Formats^*:
Category : Pharmaceutical

Global CAR T-Cell Therapy Market Introduction and Overview

According to SPER Market Research, the Global CAR T-Cell Therapy Market is estimated to reach USD 46.23 billion by 2033 with a CAGR of 28.78%.

The report includes an in-depth analysis of the Global CAR T-Cell Therapy Market, including market size and trends, product mix, applications, and supplier analysis. One of the most innovative methods for treating cancer is CAR T-cell therapy. This cutting-edge immunotherapy fights cancer by utilizing the patient's immune system. Certain hematologic malignancies, including some types of leukemia and lymphoma, have reacted remarkably well to CAR T-cell therapy, indicating its potential as a game-changing therapeutic alternative for patients who have not responded to traditional treatments.

The US FDA gave BREYANZI (lisocabtagene maraleucel) expedited approval in May 2024 to treat adult patients with relapsed or refractory Follicular Lymphoma (FL) who have had two or more lines of systemic therapy in the past.

The US FDA approved Gilead's modification of the YESCARTA (axicabtagene ciloleucel) manufacturing procedures in January 2023, lowering the median turnaround time (TAT) in the US from 16 days to 14 days.

Market Opportunities and Challenges

Opportunities- An important factor driving the market expansion for CAR T-cell treatment is the rise in leukemia prevalence. The incidence of leukemia, which is defined by the unchecked growth of aberrant white blood cells, has significantly increased in recent years. For example, the American Cancer Society estimates that over 60,650 new cases of leukemia were diagnosed in the United States in 2022. Numerous causes, such as lifestyle modifications, environmental exposures, and genetic predispositions, can be blamed for this increase A major opportunity for market growth and therapeutic breakthroughs is presented by the CAR T-cell therapy market's expansion into solid tumors. CAR T-cell treatments have historically been effective in treating hematopoietic cancers such B-cell lymphomas and acute lymphoblastic

Challenges- In the market for CAR T-cell therapy, finding patients for clinical trials is a major problem that can impede the creation and approval of new treatments. Enrolling enough patients is challenging due to the intricacy of CAR T-cell therapy trials, strict eligibility requirements, and the scarcity of target indications. The strict eligibility requirements for CAR T-cell trials are one of the main obstacles. The pool of eligible individuals is greatly reduced by these requirements, which frequently include particular genetic markers, illness subtypes, and prior treatment histories. Furthermore, patient recruitment is made more difficult by the geographical dispersion of individuals with uncommon malignancies. Rare diseases with a small patient base dispersed over huge geographic areas include relapsed large B-cell lymphoma and several forms of acute lymphoblastic leukemia (ALL).

Get more information on this report: Download Free Sample PDF

Market Competitive Landscape

The Global CAR T-Cell Therapy Market is highly consolidated. Some of the market key players are Autolus Therapeutics, Bluebird Bio, Inc., Bristol-Myers Squibb, Caribou Biosciences, Inc., Cellectis, Celgene Corporation, Celyad Oncology, Cartesian Therapeutics, Inc., Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Inc., Merck & Co., Inc., Miltenyi Biotech, Novartis AG, Pfizer, Inc.

Scope of the report:

Report Metric	Details
Market size available for years	2020-2033
Base year considered	2023
Forecast period	2024-2033
Segments covered	By Drug Type, By Indication, By End User
Regions covered	North America, Asia-Pacific, Latin America, Middle East & Africa and Europe
Companies Covered	Autolus Therapeutics, Bluebird Bio, Inc., Bristol-Myers Squibb, Caribou Biosciences, Inc., Cellectis, Celgene Corporation, Celyad Oncology, Cartesian Therapeutics, Inc., Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Inc., Merck & Co., Inc., Miltenyi Biotech, Novartis AG, Pfizer, Inc.

COVID-19 Impact on Global CAR T-Cell Therapy Market

Growth for CAR-T cell treatment slowed in 2020 as a result of the COVID-19 pandemic. The poor diagnostic rate of blood cancer during the pandemic was mostly caused by a number of issues that caused problems for the healthcare system. Furthermore, the pandemic caused supply chain disruptions, making it challenging for medical professionals to get the instruments and supplies needed to diagnose blood cancer, including imaging devices and blood tests. Furthermore, the diagnosis was made more difficult by the parallels between COVID-19 symptoms including fever, shortness of breath, and exhaustion and blood cancer. People had trouble identifying the necessity for blood cancer diagnostic testing because of these overlapping symptoms, which caused additional delays in diagnosis.

Key Target Audience:

Healthcare Providers
Patients and Caregivers
Pharmaceutical and Biotechnology Companies
Research Institutions and Academic Organizations
Investors and Financial Analysts
Regulatory Agencies
Health Insurance Providers
Medical Equipment Manufacturers

Our in-depth analysis of the Global CAR T-Cell Therapy Market includes the following segments:

By Drug Type:	Axicabtagene Ciloleucel Tisagenlecleucel Brexucabtagene Autoleucel Others
By Indication:	Lymphoma Acute Lymphocytic Leukemia Others
By End User:	Hospitals Cancer Treatment Centers

Key Topics Covered in the Report:

Global CAR T-Cell Therapy Market Size (FYâ€™2024-FYâ€™2033)
Overview of Global CAR T-Cell Therapy Market
Segmentation of Global CAR T-Cell Therapy Market By Drug Type (Axicabtage Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others)
Segmentation of Global CAR T-Cell Therapy Market By Indication (Lymphoma, Acute Lymphocytic Leukemia, Others)
Segmentation of Global CAR T-Cell Therapy Market By End User (Hospitals, Cancer Treatment Centers)
Statistical Snap of Global CAR T-Cell Therapy Market
Expansion Analysis of Global CAR T-Cell Therapy Market
Problems and Obstacles in Global CAR T-Cell Therapy Market
Competitive Landscape in the Global CAR T-Cell Therapy Market
Impact of COVID-19 and Demonetization on Global CAR T-Cell Therapy Market
Details on Current Investment in Global CAR T-Cell Therapy Market
Competitive Analysis of Global CAR T-Cell Therapy Market
Prominent Players in the Global CAR T-Cell Therapy Market
SWOT Analysis of Global CAR T-Cell Therapy Market
Global CAR T-Cell Therapy Market Future Outlook and Projections (FYâ€™2024-FYâ€™2033)
Recommendations from Analyst

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERâ€™s internal database
2.1.4. Premium insight from KOLâ€™s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global CAR T-Cell Therapy Market.

5. Market variable and outlook

5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERâ€™s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global CAR T-Cell Therapy Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global CAR T-Cell Therapy Market

7. Global CAR T-Cell Therapy Market, By Drug Type (USD Million) 2020-2033

7.1. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Drug Type, 2020-2026
7.2. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Drug Type, 2027-2033
7.3. Axicabtagene Ciloleucel
7.4. Tisagenlecleucel
7.5. Brexucabtagene Autoleucel
7.6. Others

8. Global CAR T-Cell Therapy Market, By Indication (USD Million) 2020-2033

8.1. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Indication, 2020-2026
8.2. Global CAR T-Cell Therapy Market Size, Share and Forecast, By Indication, 2027-2033
8.3. Lymphoma
8.4. Acute Lymphocytic Leukemia
8.5. Others

9. Global CAR T-Cell Therapy Market, By End User (USD Million) 2020-2033

9.1. Global CAR T-Cell Therapy Market Size, Share and Forecast, By End User, 2020-2026
9.2. Global CAR T-Cell Therapy Market Size, Share and Forecast, By End User, 2027-2033
9.3. Hospitals
9.4. Cancer Treatment Centers

10. Global CAR T-Cell Therapy Market Forecast, 2020-2033 (USD Million)

10.1. Global CAR T-Cell Therapy Market Size and Market Share

11. Global CAR T-Cell Therapy Market, By Region, 2020-2033 (USD Million)

11.1. Global CAR T-Cell Therapy Market Size and Market Share By Region (2020-2026)
11.2. Global CAR T-Cell Therapy Market Size and Market Share By Region (2027-2033)
11.3. Asia-Pacific
11.3.1. Australia
11.3.2. China
11.3.3. India
11.3.4. Japan
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4. Europe
11.4.1. France
11.4.2. Germany
11.4.3. Italy
11.4.4. Spain
11.4.5. United Kingdom
11.4.6. Rest of Europe
11.5. Middle East and Africa
11.5.1. Kingdom of Saudi Arabia
11.5.2. United Arab Emirates
11.5.3. Qatar
11.5.4. South Africa
11.5.5. Egypt
11.5.6. Morocco
11.5.7. Nigeria
11.5.8. Rest of Middle-East and Africa
11.6. North America
11.6.1. Canada
11.6.2. Mexico
11.6.3. United States
11.7. Latin America
11.7.1. Argentina
11.7.2. Brazil
11.7.3. Rest of Latin America

12. Company Profile

12.1. Autolus Therapeutics
12.1.1. Company details
12.1.2. Financial outlook
12.1.3. Product summary
12.1.4. Recent developments
12.2. Bluebird Bio, Inc.
12.2.1. Company details
12.2.2. Financial outlook
12.2.3. Product summary
12.2.4. Recent developments
12.3. Bristol-Myers Squibb
12.3.1. Company details
12.3.2. Financial outlook
12.3.3. Product summary
12.3.4. Recent developments
12.4. Caribou Biosciences, Inc.
12.4.1. Company details
12.4.2. Financial outlook
12.4.3. Product summary
12.4.4. Recent developments
12.5. Cellectis
12.5.1. Company details
12.5.2. Financial outlook
12.5.3. Product summary
12.5.4. Recent developments
12.6. Celgene Corporation
12.6.1. Company details
12.6.2. Financial outlook
12.6.3. Product summary
12.6.4. Recent developments
12.7. Celyad Oncology
12.7.1. Company details
12.7.2. Financial outlook
12.7.3. Product summary
12.7.4. Recent developments
12.8. Cartesian Therapeutics, Inc.
12.8.1. Company details
12.8.2. Financial outlook
12.8.3. Product summary
12.8.4. Recent developments
12.9. Gilead Sciences, Inc. (Kite Pharma Inc.)
12.9.1. Company details
12.9.2. Financial outlook
12.9.3. Product summary
12.9.4. Recent developments
12.10. Intellia Therapeutics
12.10.1. Company details
12.10.2. Financial outlook
12.10.3. Product summary
12.10.4. Recent developments
12.11. Juno Therapeutics, Inc.
12.11.1. Company details
12.11.2. Financial outlook
12.11.3. Product summary
12.11.4. Recent developments
12.12. Merck & Co., Inc.
12.12.1. Company details
12.12.2. Financial outlook
12.12.3. Product summary
12.12.4. Recent developments
12.13. Miltenyi Biotech
12.13.1. Company details
12.13.2. Financial outlook
12.13.3. Product summary
12.13.4. Recent developments
12.14. Novartis AG
12.14.1. Company details
12.14.2. Financial outlook
12.14.3. Product summary
12.14.4. Recent developments
12.15. Pfizer, Inc.
12.15.1. Company details
12.15.2. Financial outlook
12.15.3. Product summary
12.15.4. Recent developments
12.16. Others

13. Conclusion

14. List of Abbreviations

15. Reference Links

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3

Frequently Asked Questions About This Report

How big is the CAR T-Cell Therapy Market?

CAR T-Cell Therapy Market is projected to reach USD 46.23 billion by 2033, growing at a CAGR of 28.78% during the forecast period.

What is the growth rate of the CAR T-Cell Therapy Market?

CAR T-Cell Therapy Market grew in Market size from 2024. The Market is expected to reach USD 46.23 billion by 2033, at a CAGR of 28.78% during the forecast period.

What is the anticipated CAGR of the CAR T-Cell Therapy Market?

CAR T-Cell Therapy Market CAGR of 28.78% during the forecast period.

How can I get a sample report on the CAR T-Cell Therapy Market?

You can get the sample pages by clicking the link - Click Here

What is the Market size of the CAR T-Cell Therapy Market?

CAR T-Cell Therapy Market size is USD 46.23 billion from 2024 to 2033.

Which segment is expected to CAR T-Cell Therapy Market?

CAR T-Cell Therapy Market is covered By Drug Type, By Indication and By End User

Which region is expected to have the highest Market share in the CAR T-Cell Therapy Market?

The North America is anticipated to have the highest Market share in the CAR T-Cell Therapy Market.

Who are the key players in CAR T-Cell Therapy Market?

The Key players in the Market include Companies Covered Autolus Therapeutics, Bluebird Bio, Inc., Bristol-Myers Squibb, Caribou Biosciences, Inc., Cellectis, Celgene Corporation, Celyad Oncology, Cartesian Therapeutics, Inc., Gilead Sciences, Inc. (Kite Pharma Inc.), Intellia Therapeutics, Juno Therapeutics, Inc., Merck & Co., Inc., Miltenyi Biotech, Novartis AG, Pfizer, Inc.

What is the conclusion of the CAR T-Cell Therapy Market?

The high cost of advanced diabetes drugs and the financial burden of treating diabetes remain major obstacles to market growth, despite the fact that numerous drugs have been approved for the condition and that governments and industry players are launching numerous initiatives.